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Summary
PRINCIPLES: Prediction of arrhythmic events (AEs) has
gained importance with the availability of implantable
cardioverter-defibrillators (ICDs), but is still imprecise.
This study evaluated the innovative Wedensky modulation
index (WMI) as predictor of AEs.
METHODS: In this prospective cohort, 179 patients with
coronary artery disease (CAD) referred for AE risk as-
sessment underwent baseline evaluation including meas-
urement of R-/T-wave WMI (WMIRT) and left ventricular
ejection fraction (LVEF). Two endpoints were assessed 3
years after the baseline evaluation: sudden cardiac death or
appropriate ICD event (EP1) and any cardiac death or ap-
propriate ICD event (EP2). Associations between baseline
predictors (WMIRT and LVEF) and endpoints were evalu-
ated in regression models.
RESULTS: Only three patients were lost to follow-up. EP1
and EP2 occurred in 24 and 27 patients, respectively.
WMIRT (odds ratio [OR] per 1 point increase for EP1 20.1,
95% confidence interval [CI] 1.8–221.4, p = 0.014, and for
EP2 73.3, 95% CI 6.6–817.7, p <0.001) and LVEF (OR per
1% increase for EP1 0.94, 95% CI 0.90–0.99, p = 0.013,
and for EP2 0.93, 95% CI 0.89–0.97, p = 0.002) were sig-
nificantly associated with both endpoints. In bivariable re-
gression controlled for LVEF, WMIRT was independently
associated with EP1 (p = 0.047) and EP2 (p = 0.007). The
combination of WMIRT ≥0.60 and LVEF ≤30% resulted in
a positive predictive value of 36% for EP1 and 50% for
EP2.
CONCLUSIONS: WMIRT is a significant predictor of AEs
independent of LVEF and has potential to improve AE risk
prediction in CAD patients. However, WMIRT should be
evaluated in larger and independent samples before recom-
mendations for clinical routine can be made.
Key words: arrhythmia; cardiac; death; sudden cardiac
death; left ventricular dysfunction; Wedensky inhibition
Introduction
Implantable cardioverter-defibrillators (ICDs) can prevent
arrhythmic events (AEs) causing sudden cardiac death
(SCD) [1–3]. Therefore, guidelines recommend ICD im-
plantation in specific patient situations [4]. The currently
used criteria for ICD implantation are still far from perfect.
Depending on the criteria used for ICD implantation, num-
bers needed to treat remain high: approximately 30 ICD
implantations are required to prevent one SCD per year us-
ing the criterion of a prior myocardial infarction and a left
ventricular ejection fraction (LVEF) ≤30% [3]. Unneces-
sary ICD implantation should be avoided, because ICDs
are expensive and can cause adverse events (e.g., anxiety
disorders due to inappropriate ICD shocks, or infections)
[5]. On the other hand, many patients at risk for SCD do
not receive an ICD because the increased risk is not recog-
nised [6]. Improvements in SCD prediction are required.
Currently, LVEF is the most widely used single predictor
because it was evaluated in most of the clinical trials [1–3].
However, test characteristics of LVEF for SCD prediction
are far from perfect and LVEF determination lacks preci-
sion [7–12].
Determination of the Wedensky modulation index (WMI)
is a novel and innovative technology for SCD prediction.
WMI is based on the observation that a sub-threshold elec-
trical stimulus may alter the cellular threshold for subse-
quent depolarisation, first described by Wedensky in 1886
for neuromuscular tissue, and later described by Castel-
lanos for the human heart [13, 14]. The extent to which
heart cells alter their threshold after a sub-threshold stim-
ulus is a marker for their excitability and might therefore
be a marker for SCD risk. Several clinical studies evaluated
WMI as a SCD risk predictor and documented its ability to
stratify the risk [15–18]. However, in these previous stud-
ies patients were at the highest risk of SCD (mostly patients
who had ICDs), the sample size was small, or there was
no follow-up with hard endpoints. Therefore, this study in-
vestigated WMI in an adequately powered sample of pa-
tients with coronary artery disease (CAD) as predictor of
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AEs during 3 years of follow-up, and evaluated its ability
to enhance risk prediction models based on LVEF.
Methods
Study population
Consecutive patients referred for SCD risk evaluation to
Luzerner Kantonsspital (Luzern, Switzerland) during a
4–year period (between 1 October 2003 and 30 September
2007) were eligible for this prospective cohort study. In
general, patients were referred for SCD risk evaluation if
they were considered at increased risk for SCD (e.g., after
myocardial infarction, after a syncope, after resuscitation,
due to a low LVEF and/or due to ventricular tachycar-
dia/fibrillation [VT/VF] during monitoring). Patients were
included in the study if they had CAD. CAD was con-
sidered to be present if coronary angiography revealed at
least one coronary stenosis of ≥50% in one of the coronary
vessels or if the patient had an acute coronary syndrome
(ACS) caused by coronary vasospasm. Patients who did
not provide written informed consent were excluded. The
study complies with the Declaration of Helsinki and was
approved by the local ethics committee.
Baseline data
All participating patients underwent an extensive baseline
examination. Patient history, including symptoms, cardi-
Figure 1
The device for Wedensky modulation consists of a standard
computer system equipped with an adapter for the special
electrodes and software for analysis of the ECG signal (a). The set
of electrodes includes two large-size electrodes for the application
of sub-threshold stimuli, which are placed on the sternum and back,
and seven small-size electrodes for the recording of a high
resolution ECG (b). Example of an ECG recording (c): the white tick
marks show where the software detected an R-wave, and the red
tick marks show when a sub-threshold stimulus was delivered.
ECG recordings are analysed using three-dimensional Morlet
wavelet transformation separately for stimulated and non-
stimulated heart beats. The wavelet transformation averages the
vector magnitude of the beats, separates the frequency of the
beats, and displays the results as a three-dimensional surface
whose axes are time (x axis), frequency (y axis), and amplitude (z
axis) (d). To reveal the difference between the stimulated and non-
stimulated beats the surfaces are arithmetically subtracted resulting
in a wavelet residuum (e). Any variation in the wavelet residuum
plane represents a response caused by the stimulation. The key
indicators of the wavelet residuum are mathematically combined to
calculate the Wedensky modulation index.
ovascular risk factors, medication, prior cardiovascular
events and further comorbidities, was recorded. Physical
examination included the measurement of weight, height,
blood pressure and heart rate. An electrocardiogram (ECG)
was recorded in all patients. All patients underwent cardiac
catheterisation to provide information about the presence
of CAD. LVEF was measured with transthoracic echocar-
diography in all patients and was determined on two- and
four-chamber views using the modified biplane Simpson
method.
WMI was determined using a novel device (MI-1000,
Harbinger Medical Inc., Eden Prairie, Minnesota, USA)
(fig. 1). The device is capable of applying electrical sub-
threshold stimuli of 5 mA for 2 ms via two electrodes
which are placed on the patient’s thorax. The device re-
cords a high resolution ECG of approximately 1,000 heart-
beats. The first 200 heartbeats are recorded without any
stimulation. During the next 400 heartbeats, a sub-
threshold stimulus is applied to every second heartbeat syn-
chronised with the R-wave. During the last 400 heartbeats,
the stimulus is applied 20 ms after the R-wave. The record-
ings are analysed using a three-dimensional Morlet wave-
let surface calculation from stimulated and non-stimulated
heart beats (fig. 1) [19, 20]. Previous studies showed that
patients with increased SCD risk are less sensitive to the
sub-threshold stimulus, and the wavelet surface of the high
resolution ECG alters to a lesser extent [15–17]. Based on
the difference of the wavelet surfaces between stimulated
and non-stimulated heart beats, WMI is calculated separ-
ately for the R-wave (WMIR) and the T-wave (WMIT). The
higher of both WMIs is then selected for the combined
WMIRT, which was evaluated as a SCD predictor in this
study. WMIRT values range between 0 and 1 with higher
values indicating higher SCD risk.
Follow-up data
Follow-up data were recorded at exactly 3 years after the
baseline examination. Follow-up data were obtained from
several sources. All patients were contacted by telephone.
In addition, ICD protocols of all patients treated with an
ICD were reviewed. Surviving patients were interviewed
by telephone using a structured protocol. If the patient re-
ported a possible AE, additional information was obtained
from the hospital case record and/or general practitioner.
For patients who died, additional information on the cir-
cumstances of death was collected by interviewing the pa-
tient’s relatives and/or general practitioner and/or by study-
ing the hospital case record.
The present study evaluated two endpoints: first, SCD or
sustained VT/VF terminated appropriately by ICD shock
or ICD antitachycardia pacing (endpoint 1); and second,
any cardiac death (including SCD) or sustained VT/VF ter-
minated appropriately by ICD shock or ICD antitachycar-
dia pacing (endpoint 2). AEs were independently classified
by two physicians who were blinded to baseline data. For
death classification, the Hinkle-Thaler method was used
[21]. If a patient experienced more than one endpoint event
(e.g., termination of a sustained VT/VF by ICD in a patient
who later died from a cardiac cause), only the first endpoint
event was considered.
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Statistical analysis
First, mortality and arrhythmic events during follow-up
were descriptively analysed. Second, the associations
between the baseline predictors (WMIRT and LVEF) and
the endpoints were evaluated in uni- and multivariable lo-
gistic regression models providing odds ratios (ORs). Pre-
dictors were analysed as continuous and dichotomised
measures. As continuous measures, the predictors were
used linearly (after checking for a potential quadratic re-
lationship with the endpoints). For their use as dichotom-
ised measures, predictors were dichotomised at cut-points
based on the following considerations: first, current eviden-
ce from literature, and second, a cut-point close to the 25th
percentile of the predictor (hereby generating for both pre-
dictors a high-risk population of about one quarter of the
overall study population) [1–3, 15–18]. This resulted in the
following cut points: WMIRT ≥0.60 (indicating higher risk)
vs <0.60 (indicating lower risk) and LVEF ≤30% (indic-
ating higher risk) vs LVEF >30% (indicating lower risk).
Postestimation after logistic regression included the calcu-
lation of the area under the receiver operating characterist-
ic curve (AUROC) for each predictor separately, as well
as for the combination of both predictors [22]. Sensitivity,
specificity, positive predictive value (PPV), and negative
predictive value (NPV) were calculated for both dichotom-
ised predictors. Kaplan-Meier survivor functions were gen-
erated to illustrate the ability to stratify the risk for each
dichotomised predictor separately, as well as for a combin-
ation of both predictors [23]. Predictors were combined by
defining the following three groups: both predictors con-
comitantly indicating lower risk (WMIRT <0.60 and LVEF
>30%), one of the two predictors indicating higher risk
(WMIRT ≥0.60 or LVEF ≤30%), and both predictors con-
comitantly indicating higher risk (WMIRT ≥0.60 and LVEF
≤30%). The log-rank test was used to examine equality of
survivor functions. The Kruskal-Wallis rank test was used
to compare the PPV of the combined predictors with LVEF
alone. Sensitivity analyses were performed in the primary
prevention patients. The required sample size was calcu-
lated a priori to be 177 patients on the basis of the follow-
ing assumptions: power 0.80, alpha 0.05, endpoint rate 5%/
year, predictor indicating higher risk doubles risk for en-
dpoint after 3 years. Data were analysed using Stata 11.2
(StataCorp LP, College Station, TX, USA).
Results
Study population
Between 1 October 2003 and 30 September 2007, 231
patients were referred for SCD risk evaluation. Of these,
52 patients (23%) were excluded because they fulfilled
an exclusion criterion (fig. 2). Most of the excluded pa-
tients suffered from dilated cardiopathy without CAD. Of
note, none of the eligible patients refused study participa-
tion. The study population finally consisted of 179 patients.
Of these, only five patients (3%) did not undergo 3–year
follow-up: three patients were foreign workers in Switzer-
land at the time of study inclusion who later moved away
to their country of origin and were not contactable, one pa-
tient received heart transplantation during follow-up, and
one patient died during baseline evaluation when examina-
tions were not yet completed. The study population finally
consisted of 174 patients with complete follow-up inform-
ation.
Baseline data
Baseline characteristics of the study participants who com-
pleted follow-up are shown in table 1. Mean age was 59 ±
standard deviation of 9 years (range 35–78 years). Twenty-
one participants (12%) were women. In accordance with
the inclusion criteria, all patients had CAD of whom 165
patients (95%) previously had an ACS. A percutaneous
Figure 2
Flow chart – patient disposition during study.
CAD = coronary artery disease; SCD = sudden cardiac death
Figure 3
Kaplan-Meier survival estimates for Wedensky modulation index
(WMIRT), left ventricular ejection fraction (LVEF) and the
combination of both predictors (Group 1 = WMIRT <0.60 and LVEF
>30%; Group 2 = WMIRT ≥0.60 or LVEF ≤30%; Group 3 = WMIRT
≥0.60 and LVEF ≤30%).
ICD = implantable cardioverter-defibrillator; SCD = sudden cardiac
death; VT/VF = ventricular tachycardia / ventricular fibrillation
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coronary intervention was performed in 137 patients (79%)
of whom 133 patients (97%) also received stent implant-
ation. A substantial proportion, 96 patients (55%), had an
ICD and were checked in hospital at yearly intervals. Of
these, an ICD was implanted for primary prevention in 80
patients (83%) and for secondary prevention after abor-
ted SCD in 16 patients (17%). The decision for ICD im-
plantation in primary prevention patients was based on a
comprehensive clinical evaluation, including LVEF, find-
ings from rhythm monitoring, and/or invasive evaluation.
Forty-six of 80 primary prevention patients (58%) had an
LVEF <35%.
Mean values of the two baseline predictors (WMIRT and
LVEF) are shown in table 1. The WMIRT had a maximum
range from 0.16 to 1.00, the LVEF from 17% to 70%.
After dichotomisation, 50 patients (29%) were considered
at higher risk according to the WMIRT, and 54 patients
(31%) according to the LVEF. Only 22 patients were con-
comitantly rated higher risk by both predictors. In 90 pa-
tients (55%) of the 165 with a previous ACS, the predictors
were measured within 1 month after the ACS. Both
baseline predictors (WMIRT and LVEF) were available for
all study participants and there were no missing values due
to technical errors.
Follow-up data
Overall, 15 patients (9%) died during the 3–year follow-
up. Causes of death were: SCD in 5 patients (33%), con-
gestive heart failure in 5 patients (33%), cancer in 2 pa-
tients (13%), pneumonia in one patient (7%), intra-oper-
ative death in one patient (7%), and unclear cause in one
patient (7%). Twenty-four patients (14%) experienced an
endpoint 1 event (SCD in 4 patients and sustained VT/VF
terminated appropriately by ICD in 20 patients), and 27 pa-
tients (16%) an endpoint 2 event (as compared with end-
point 1, cardiac death as a result of congestive heart failure
in an additional 3 patients). Inappropriate ICD shocks not
counting as endpoint events were observed during follow-
up in 12 patients (7%). Among patients who experienced a
non-fatal endpoint event, three died later in the course of
the study: SCD occurred in one patient; one patient died of
congestive heart failure; and one patient died after the ICD
was inactivated, because overall treatment was changed to
palliation.
Associations between predictors and endpoints
Uni- and bi-variable associations of predictors with the
endpoints from logistic regression and postestimation of
AUROC are shown in table 2. Bivariable logistic regres-
sion revealed independent associations with the endpoints
for both predictors. Test characteristics of both dichotom-
ised predictors were similar. For endpoint 1, WMIRT had
a sensitivity of 50%, a specificity of 75%, a PPV of 24%,
and an NPV of 90%; LVEF had a sensitivity of 54%, a spe-
cificity of 73%, a PPV of 24%, and an NPV of 91%. For
endpoint 2, WMIRT had a sensitivity of 56%, a specificity
of 76%, a PPV of 30%, and an NPV of 90%; LVEF had a
sensitivity of 59%, a specificity of 74%, a PPV of 30%, and
an NPV of 91%.
Figure 3 shows the Kaplan-Meier survival estimates for
WMIRT, LVEF and the combination of both predictors for
the prediction of both endpoints. Of note, the combination
of a WMIRT ≥0.60 and LVEF ≤30% resulted in a PPV of
36% for endpoint 1 and of 50% for endpoint 2. Compared
with LVEF alone, the increase in PPV with use of both pre-
dictors combined was not significant (p = 0.280 for end-
point 1 and p = 0.095 for endpoint 2).
Sensitivity analyses
In the 147 primary prevention patients, sensitivity analyses
revealed that WMIRT (OR per 1 point increase for endpoint
1 = 30.0, 95% confidence interval [CI] 2.3–397.8, p =
0.010, and for endpoint 2 = 130.5, 95% CI 9.1–1,871.0, p
<0.001) and LVEF (OR per 1% increase for endpoint 1 =
0.94, 95% CI 0.89–0.99, P = 0.017, and for endpoint 2=
0.92, 95% CI 0.88 – 0.97, p = 0.002) were significantly as-
sociated with both endpoints.
Discussion
This prospective longitudinal cohort study in CAD patients
shows that WMIRT is a significant predictor of AEs. Bivari-
able regression analysis of WMIRT revealed that it is a pre-
dictor independent of LVEF. The ability of WMIRT to strat-
ify the risk is comparable to that of LVEF, as shown by
similar AUROCs as well as by the test characteristics after
dichotomisation. AUROCs and Kaplan-Meier curves sug-
gest that WMIRT has the potential to enhance risk predic-
tion models based on LVEF, but this study was not large
enough to develop such a risk prediction model.
To our knowledge the present study is the first study to
evaluate WMIRT as predictor of AEs in a larger lower
risk sample that also included patients without ICD. Most
of the previously published WMI studies correlated WMI
with other markers of increased SCD risk and did not
use follow-up data to study its ability to stratify the risk
[16–18]. Only one recent large study evaluated WMI as
predictor of AEs and used prospective follow-up data [15].
However, this study was confined to high-risk patients who
had received an ICD. Therefore, in the authors’ opinion,
the present study adds to current literature.
Test characteristics of the WMIRT in the present study were
comparable to other risk predictors in clinical use for SCD
risk stratification [7–12]. Test characteristics found for
LVEF in the present study were similar to those found for
LVEF in previous studies [7–12]. In general, non-invas-
ive SCD risk predictors have good NPVs of 90% or more.
However, it is an issue that PPVs of most SCD risk predict-
ors are below 40%, which is too low to efficiently guide
ICD therapy using a single predictor. The same holds true
for WMIRT in the present study. Therefore, WMIRT is not
suitable for use as a single predictor in clinical routine, but,
as an independent predictor, might be of use in combina-
tion with other risk predictors.
This study has some limitations. First, the findings of this
study are based on data from a single centre. Therefore,
confirmation in an independent sample is of importance
to improve generalisability of the findings of the present
study. Second, in accordance with the inclusion and exclu-
sion criteria, the study population was heterogeneous with
regard to ICD indications. The study population included
patients who needed an ICD for primary prevention, pa-
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tients who needed an ICD for secondary prevention, and
patients who did not need an ICD. Therefore, test char-
acteristics of WMI and LVEF might be different if only
applied to one of these subgroups. Third, the sample size
was rather small, with 174 patients. This number and the
resulting number of endpoints were not sufficient to eval-
Table 1: Baseline characteristics.
Characteristic All study participants
(n = 174)
Age, mean ± SD, years 59 ± 9
Female sex, n (%) 21 (12)
Body Mass Index, mean ± SD, kg/m2 27 ± 4
Cardiovascular risk factors
Hypertension, n (%) 83 (48)
Hypercholesterolaemia, n (%) 122 (70)
Smoker, n (%) 117 (67)
Diabetes, n (%) 47 (27)
Positive family history for CAD, n (%) 50 (29)
Positive family history for SCD, n (%) 8 (5)
Medical history
CAD, n (%)
– One-vessel, n (%)
– Two-vessel, n (%)
– Three-vessel, n (%)
– ACS caused by vasospasm, n (%)
174 (100)
56 (32)
56 (32)
59 (34)
3 (2)
Previous ACS, n (%) 165 (95)
Previous PCI, n (%) 137 (79)
Previous resuscitation, n (%) 27 (16)
ECG
Corrected QT duration, mean ± SD, ms 454 ± 80
Left bundle branch block, n (%) 21 (12)
Right bundle branch block, n (%) 16 (9)
Laboratory
Creatinine, mean ± SD, µmol/l 91 ± 40
Wedensky modulation
WMIRT, mean ± SD, % 0.52 ± 0.17
Echocardiography
LVEF, mean ± SD, % 38 ± 11
Treatment after SCD risk evaluation
ICD, n (%) 96 (55)
Beta-blocker, n (%) 144 (83)
ACEI, n (%) 143 (82)
Diuretics, n (%) 94 (54)
ACEI = angiotensin converting enzyme inhibitor; ACS = acute coronary syndrome; CAD = coronary artery disease; ECG = electrocardiogram; ICD = implantable
cardioverter-defibrillator; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; SCD, sudden cardiac death; SD = standard deviation; WMI =
Wedensky modulation index
Table 2: Uni- and bi-variable associations of predictors with endpoint 1 (SCD or sustained VT/VF terminated appropriately by ICD) and endpoint 2 (any cardiac death or
sustained VT/VF terminated appropriately by ICD) using logistic regression and postestimation of the area under the receiver operating characteristic curve (AUROC).
Each predictor was assessed as linear measure and after dichotomisation at standard cut points.
Predictor Endpoint 1 Endpoint 2
OR (95% CI) p-value AUROC (95% CI) OR (95% CI) p-value AUROC (95% CI)
Univariable associations
WMIRT
– linear (OR per 1 point increase)
– dichotomised (≥0.60 vs <0.60)
20.1 (1.8–221.4)
2.9 (1.2–7.1)
0.014
0.016
0.64 (0.51–0.76)
0.62 (0.52–0.73)
73.3 (6.6–817.7)
4.0 (1.7–9.3)
<0.001
0.001
0.68 (0.56–0.80)
0.66 (0.56–0.76)
LVEF
– linear (OR per 1% increase)
– dichotomised (≤30% vs >30%)
0.94 (0.90–0.99)
3.1 (1.3–7.6)
0.013
0.011
0.67 (0.56–0.79)
0.63 (0.53–0.74)
0.93 (0.89–0.97)
4.2 (1.8–9.8)
0.002
0.001
0.71 (0.60–0.82)
0.67 (0.57–0.77)
Bivariable associations
WMIRT linear
LVEF linear
(p-value from global LR χ2)
8.7 (0.7–109.2)
0.96 (0.91–1.00)
0.095
0.057
0.007
0.70 (0.58–0.82) 28.4 (2.3–354.0)
0.95 (0.90–0.99)
0.009
0.021
<0.001
0.74 (0.63–0.85)
WMIRT dichotomised
LVEF dichotomised
(p-value from global LR χ2)
2.5 (1.0–6.2)
2.7 (1.1–6.7)
0.047
0.030
0.006
0.68 (0.56–0.80) 3.4 (1.4–8.1)
3.5 (1.5–8.5)
0.007
0.005
<0.001
0.72 (0.61–0.83)
AUROC = area under the receiver operating characteristic curve; CI = confidence interval; ICD = implantable cardioverter-defibrillator; LVEF = left ventricular ejection
fraction; OR = odds ratio; SCD = sudden cardiac death; VT/VF = ventricular tachycardia / ventricular fibrillation; WMI = Wedensky modulation index
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uate the WMIRT in multivariable models involving more
than two predictor variables [24]. Furthermore, the sample
size was not sufficient to prove whether or not WMIRT en-
hances risk prediction models based on LVEF. However,
the sample size was adequate to prove the main hypothesis
that WMIRT is a significant predictor independent of LVEF
as shown by the corresponding confidence intervals.
Fourth, sustained VT/VF terminated appropriately by ICD
is a weak endpoint event, because in not all circumstances
SCD would have resulted if the ICD shock was not de-
livered. Fifth, the method for WMIRT determination is new
and an explanation why ECG morphology should alter
after sub-threshold stimulation is still lacking. Sixth, the
choice of cut-points for WMIRT and LVEF is essentially ar-
bitrary and different cut-points would yield different res-
ults.
As a consequence of these limitations, there are research
implications. First, because the technology is novel and in-
novative, one may assume that there is potential for fur-
ther developments. Second, studies based on larger sample
sizes are needed for the derivation and validation of risk
scores combining WMIRT with other scores that have been
found to be predictive of SCD. It is likely that this results
in further improvement of SCD prediction. Third, WMIRT
might also be evaluated in ICD intervention trials as risk
predictor.
The present study shows that the novel and innovative
WMIRT was a strong predictor of AEs in CAD patients
over a 3-year follow-up period. WMIRT has the potential
to improve SCD risk prediction models. However, WMIRT
should be evaluated in larger and independent samples be-
fore useful recommendations for clinical routine can be
made.
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Figures (large format)
Figure 1
The device for Wedensky modulation consists of a standard computer system equipped with an adapter for the special electrodes and software
for analysis of the ECG signal (a). The set of electrodes includes two large-size electrodes for the application of sub-threshold stimuli, which are
placed on the sternum and back, and seven small-size electrodes for the recording of a high resolution ECG (b). Example of an ECG recording
(c): the white tick marks show where the software detected an R-wave, and the red tick marks show when a sub-threshold stimulus was
delivered. ECG recordings are analysed using three-dimensional Morlet wavelet transformation separately for stimulated and non-stimulated
heart beats. The wavelet transformation averages the vector magnitude of the beats, separates the frequency of the beats, and displays the
results as a three-dimensional surface whose axes are time (x axis), frequency (y axis), and amplitude (z axis) (d). To reveal the difference
between the stimulated and non-stimulated beats the surfaces are arithmetically subtracted resulting in a wavelet residuum (e). Any variation in
the wavelet residuum plane represents a response caused by the stimulation. The key indicators of the wavelet residuum are mathematically
combined to calculate the Wedensky modulation index.
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Figure 2
Flow chart – patient disposition during study.
CAD = coronary artery disease; SCD = sudden cardiac death
Original article Swiss Med Wkly. 2014;144:w13929
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 9 of 10
Figure 3
Kaplan-Meier survival estimates for Wedensky modulation index (WMIRT), left ventricular ejection fraction (LVEF) and the combination of both
predictors (Group 1 = WMIRT <0.60 and LVEF >30%; Group 2 = WMIRT ≥0.60 or LVEF ≤30%; Group 3 = WMIRT ≥0.60 and LVEF ≤30%).
ICD = implantable cardioverter-defibrillator; SCD = sudden cardiac death; VT/VF = ventricular tachycardia / ventricular fibrillation
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